Article info
PDFEditorial
Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug
- Correspondence to Michael W Stewart, Associate Professor and Chairman, Department of Ophthalmology, Mayo Clinic Florida, 4500 San Pablo Rd., Jacksonville, FL 32224, USA; stewart.michael{at}mayo.edu
Citation
Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug
Publication history
- First published March 23, 2012.
Online issue publication
July 30, 2016
Article Versions
- Previous version (29 July 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.